88 results about "Drug suspension" patented technology

Suspending vehicles and pharmaceutical suspensions that include a biocompatible polymer that can be combined with a hydrophobic solvent and a hydrophilic solvent to provide vehicles and suspensions that are substantially free of stiff gels upon contact with an aqueous medium are provided. Vehicles and suspensions remain flowable out of a pump-driven dosage form over the life of the dosage form. Such vehicles and suspensions are also biocompatible, suitable for creating and maintaining drug suspensions, and capable of providing stable drug formulations.

Liquid polyoxaester polymer materials are provided as suspending vehicles suitable for dispensing of pharmaceutically active agents, such as proteins, from delivery devices, for example, pump-driven dosage forms. Polyoxaesters are made from at least one diacid and at least one diol. Through the use of polyoxaesters virtually solvent-free pharmaceutical suspensions can be created.

Pharmaceutical suspension aerosol formulations containing a therapeutically effective amount of a drug and HFC 134a, HFC 227, or a mixture thereof.

An aqueous oral liquid pharmaceutical composition system with reduced propensity for agglomeration and phase separation which is particularly amendable to the suspension of one or more pharmaceutical actives that are substantially insoluble in water. The oral liquid pharmaceutical composition may further comprise pharmaceutical actives that are soluble in water and dissolve in the aqueous medium. In the composition of the invention both suspended and any dissolved active agents are distributed homogeneously.

Stable aqueous pharmaceutical suspension compositions containing lecithin as a stabilizing additive and lacking a polymeric suspending agent are disclosed.

A liquid pharmaceutical composition comprises an aqueous medium having suspended therein a solid particulate Bc1-2 family protein inhibitory compound such as ABT-263, having a D90 particle size not greater than about 3 μm; wherein the aqueous medium further comprises at least one pharmaceutically acceptable surfactant and at least one pharmaceutically acceptable basifying agent such as sodium bicarbonate in amounts that are effective together to inhibit particle size increase. The composition is suitable for oral or parenteral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bc1-2 family proteins, for example cancer.

Liquid polyoxaester polymer materials are provided as suspending vehicles suitable for dispensing of pharmaceutically active agents, such as proteins, from delivery devices, for example, pump-driven dosage forms. Polyoxaesters are made from at least one diacid and at least one diol. Through the use of polyoxaesters virtually solvent-free pharmaceutical suspensions can be created.

An aqueous oral liquid pharmaceutical composition system with reduced propensity for agglomeration and phase separation which is particularly amendable to the suspension of one or more pharmaceutical actives that are substantially insoluble in water. The oral liquid pharmaceutical composition may further comprise pharmaceutical actives that are soluble in water and dissolve in the aqueous medium. In the composition of the invention both suspended and any dissolved active agents are distributed homogeneously.

A conducting silicone matrix incorporating a suspension of a drug in ionized and non-ionized phases in an emulsion of a hydrophobic polymer. In one version, the drug is prepared as a concentrated aqueous suspension incorporated in a silicone matrix with a silicone surfactant. An electrolyte may be incorporated into the silicone matrix for increasing its conductivity. When a current is applied, the drug in individual globules in the drug suspension migrates away from the electrode and becomes concentrated at the distal side of the globules eventually resulting in an increase in the drug concentration distal to the electrode and adjacent to the skin and thereby resulting in transfer of the active drug through the skin. This system provides a matrix with minimal electroendosmotic flow that is current efficient and provides a drug reservoir that can last for several days during application of the drug.

The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved since the first day up to at least 14 days or more even up to at least four weeks.

The invention relates to andrographolide ground suspending liquid, a preparation method thereof, and the application of pharmaceutical preparation, which belongs to the field of pharmaceutical preparation. The preparation method comprises the steps of adding andrographolide into hydrophilic accessory solution with certain concentration, and grinding the andrographolide in a basket grinder to prepare suspending liquid with particle sizes smaller than 3000 nm. Liquid layers of pharmaceutical suspending liquid are laminated onto blank pellet cores with certain particle size range, to prepare andrographolide immediate-release pellets. After grinding, by reducing pharmaceutical particle sizes, increasing particle surface areas and improving the wettability of pharmaceutical particles, the dissolution in vitro of the drug is improved, and hydrophilic carriers are adopted to effectively prevent the aggregation of pharmaceutical particles so as to improve the stability of the pharmaceutical preparation. The preparation method is simple and easy for industrialized production, and the dissolving-out speed of the prepared andrographolide immediate-release pellets is high, so that the bioavailability is obviously improved.

The invention relates to the formulation and quality control of liquid drug suspensions. In particular, the invention relates to methods of formulating liquid suspensions comprising drug-containing resin particles. The invention also relates to methods of confirming the acceptability of drug-containing resin particles for use in formulating liquid drug suspensions. The invention further relates to methods of formulating liquid suspensions in which drug-containing resin particles, the liquid suspension, or both are modified to achieve a desired in vitro dissolution profile. The invention also relates to a novel dissolution method and methods of predicting in vivo bioequivalence based on in vitro dissolution methods.

The invention features a pharmaceutical suspension containing drug particles, a drug delivery device anchored in the mouth for continuously administering the pharmaceutical suspension, and methods of their use.

A drug delivery device is provided herein, the device including a reservoir for containing a medicament. The medicament includes a suspension of solids in a liquid carrier. The device also includes a needle having a distal end for injection into a patient, a proximal end in communication with the reservoir, and a lumen extending between the distal and proximal ends. A path is defined from the reservoir to the distal end of the needle through the lumen, the path having an inner diameter that decreases in the proximal to distal direction along at least a portion thereof. Advantageously, with the subject invention, a flow path may be defined which provides a more gradual transition in diameter from the reservoir to the distal tip of a needle. In this manner, changes in velocity of the suspension may be less abrupt than in the prior art, thus better maintaining solid particles in the suspension.

The invention relates to the formulation and quality control of liquid drug suspensions. In particular, the invention relates to methods of formulating liquid suspensions comprising drug-containing resin particles. The invention also relates to methods of confirming the acceptability of drug-containing resin particles for use in formulating liquid drug suspensions. The invention further relates to methods of formulating liquid suspensions in which drug-containing resin particles, the liquid suspension, or both are modified to achieve a desired in vitro dissolution profile. The invention also relates to a novel dissolution method and methods of predicting in vivo bioequivalence based on in vitro dissolution methods.

The present invention is process of preparing gemfibrozil medicine powder, and belongs to the field of insoluble medicine micronizing technology. Through dissolving gemfibrozil medicine in water solution of sodium hydroxide, neutralizing and replacing with added water solution of hydrochloric acid containing surfactant to obtain suspension of gemfibrozil medicine, filtering, washing and drying, spheroid gemfibrozil medicine powder in submicron size is produced. The process is simple, low in cost and easy in industrial application, and the obtained gemfibrozil medicine powder has regular shape, narrow size distribution and high dispersivity. The present invention lays foundation for the industrial production and the new preparation form development of gemfibrozil medicine.

The present invention provides pharmaceutical suspensions of D-methionine in which the aqueous solubility of D-methionine is exceeded, thereby allowing oral administration of higher doses. The present invention also provides processes for preparing these suspensions. The present invention further provides methods for preventing, treating, or ameliorating oral mucositis, hearing loss due to chemotherapy, antibiotics and noise, neuronal damage due to various CNS disorders and injuries, and anthracycline toxicity.

The present invention in general relates to a pharmaceutical suspension comprising nano-sized cocrystals of at least one active ingredient and at least one dicarboxylic acid. It in particular relates to a pharmaceutical suspension comprising nano-sized cocrystals of at least one anthelmintic drug and at least one dicarboxylic acid. The invention further relates to uses, methods for use and methods for manufacturing the pharmaceutical suspension according to this invention.

Density-matching is used to provide suspending vehicles, pharmaceutical suspensions, dosage forms, and kits as well as methods of making and using the vehicles, suspensions, and dosage forms. Pharmaceutical suspensions comprising a pharmaceutically active agent having an active agent density, ρA, and a suspending vehicle having a suspending vehicle density, ρSV; wherein the suspending vehicle density, ρSV is substantially equal to the active agent density, ρA, are provided. Suspending vehicles comprise at least one suspending agent. The suspending vehicles can further comprise at least one density-modifying solid in such a combination with the suspending agent as to create a suspending vehicle that has a density that substantially matches the density of a desired drug particle or combination of drug particles. Pharmaceutical suspensions that remain homogenous during prolonged storage can be obtained.

The invention belongs to the field of medicine preparation, and particularly relates to a preparation method of a poorly soluble medicine liposome. A blank liposome free of a medicine and a medicine suspension or a medicine solution are separately prepared, and then the blank liposome and the medicine are mixed under the conditions of a certain temperature and a certain rotating speed. According to the poorly soluble medicine liposome prepared by the method, the encapsulation efficiency is greater than or equal to 90%, and the mean grain size is smaller than or equal to 150nm. According to the preparation method, conventional process equipment is adopted, the product is stable in quality, the method is simple in technology, and low in cost, and the technical problem that the poorly soluble medicine liposome is difficultly industrialized is solved.

A device and method for administering a consistent and steady dosage of Metformin to patients which includes an implantation component with a composition of Metformin adapted to be inserted either subdermally or subcutaneously to administer a steady incremental dosage of Metformin to the patient throughout a predetermined period of time. A Metformin drug suspension is dispersed in a plurality of microreservoirs and the mixture of microreservoirs and placed in a silicone polymer tube for in situ polymerization and molding, which would allow Metformin molecules to initially diffuse through the microreservoir membrane and then through the silicone polymer containing membrane. In a further embodiment, Metformin implants may be formed by dispersing the drug in a copolymer matrix, which is then coated with a copolymer that serves as a rate-controlling membrane. The drug permeation through the polymer membrane occurs at a rate that is slower than that through the polymer matrix.

The invention discloses a method for rapidly dissolving / swelling a water-soluble high polymer suspending agent in drug suspension. The method comprises the following steps: adding the suspending agentinto an organic solvent mixable with water, uniformly stirring and mixing until no granule exists, and adding the organic solvent with the suspending agent dispersed therein into a dispersion mediumcontaining drugs and excipients. When the suspended solution is prepared by the traditional method, the high polymer suspending agent easily floats on the water surface or block mass that is wet in exterior and dry in interior is formed, the suspending agent needs to be added into water to be uniformly stirred and mixed in the small-amount multiple manner, and the agent needs to be completely dissolved or swelled in water within 10-20 hours even longer time. Moreover, when the high polymer suspending agent is dispersed in the organic solvent, the suspending agent can be directly added into theorganic solvent, uniformly stirred and mixed and then mixed with the aqueous solution, the dispersed suspending agent can be rapidly and fully contacted with water and can be fully dissolved or swelled within 5-30 minutes, the drug preparation time can be greatly saved, and the production efficiency is improved.

The present invention is directed to the provision of a pharmaceutical suspension. The suspension includes high molecular weight polyethylene glycol as a suspending agent. The suspension also typically includes an antimicrobial agent (e.g., polymeric quaternary ammonium compound), an antimicrobial system (e.g., borate / polyol complex system) or both. The suspension has been found particularly useful as an ophthalmic suspension, but can be used in other instances as well.